Open-Label Extension Study to Evaluate the Long Term Safety and Efficacy of ESK-001 in Plaque Psoriasis
NCT05739435 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 165
Last updated 2026-04-01
Summary
This is a multi-center, open-label extension (OLE) study in patients with plaque psoriasis who have completed their participation in a previous plaque psoriasis study of ESK-001.
Conditions
Interventions
- DRUG
-
envudeucitinib
Oral tablet
Sponsors & Collaborators
-
Alumis Inc
lead INDUSTRY
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2023-01-17
- Primary Completion
- 2026-12-01
- Completion
- 2026-12-30
- FDA Drug
- Yes
Countries
- United States
- Canada
Study Locations
More Related Trials
-
Efficacy and Safety of Subcutaneous Secukinumab for Moderate to Severe Chronic Plaque-type Psoriasis for up to 1 Year
NCT01365455 ·Status: COMPLETED ·Phase: PHASE3
-
Safety and Efficacy of Secukinumab Compared to Etanercept in Subjects With Moderate to Severe, Chronic Plaque-Type Psoriasis
NCT01358578 ·Status: COMPLETED ·Phase: PHASE3
-
Extension Study of Secukinumab Prefilled Syringes in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis Completing Preceding Psoriasis Phase III Studies With Secukinumab
NCT01544595 ·Status: COMPLETED ·Phase: PHASE3
-
A Study of AK111 in Healthy Subjects
NCT03622021 ·Status: COMPLETED ·Phase: PHASE1
-
Open-label Study of Subcutaneous Secukinumab to Evaluate Efficacy and Safety in Patients With Plaque Psoriasis Who Had Inadequate Response to Cyclosporine A
NCT02547714 ·Status: COMPLETED ·Phase: PHASE4
-
A Safety and Efficacy Study of Ustekinumab in Patients With Plaque Psoriasis Who Have Had an Inadequate Response to Methotrexate
NCT01059773 ·Status: COMPLETED ·Phase: PHASE4
-
AIN457 Regimen Finding Extension Study in Participants With Moderate to Severe Psoriasis
NCT01132612 ·Status: COMPLETED ·Phase: PHASE2
-
A Phase 3 Study in Participants With Moderate to Severe Psoriasis
NCT01474512 ·Status: COMPLETED ·Phase: PHASE3
-
Efficacy of Secukinumab Compared to Ustekinumab in Patients With Plaque-type Psoriasis
NCT02074982 ·Status: COMPLETED ·Phase: PHASE3
-
4 Year Extension Study of Efficacy and Safety of Secukinumab in Patients With Moderate to Severe Chronic Plaque-type Psoriasis
NCT01640951 ·Status: COMPLETED ·Phase: PHASE3
-
Study of Efficacy and Safety of Secukinumab 2 mL Auto-injector (300 mg) in Subjects With Moderate to Severe Plaque Psoriasis
NCT03589885 ·Status: COMPLETED ·Phase: PHASE3
-
The Safety & Efficacy of Etanercept in Psoriasis Patients Who Have Not Responded to Adalimumab
NCT00833729 ·Status: COMPLETED ·Phase: PHASE4
-
Open Label Study to Evaluate the Safety and Efficacy of AK101 Injection Subcutaneously in Subjects With Psoriasis
NCT05509361 ·Status: COMPLETED ·Phase: PHASE3
-
Study of Efficacy and Safety of Secukinumab in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis
NCT03066609 ·Status: COMPLETED ·Phase: PHASE3
-
First Study of Secukinumab in Pre-filled Syringes in Subjects With Chronic Plaque-type Psoriasis: Response at 12 Weeks
NCT01555125 ·Status: COMPLETED ·Phase: PHASE3
-
Efficacy and Safety of Subcutaneous Secukinumab (AIN457) for Moderate to Severe Chronic Plaque-type Psoriasis Assessing Different Doses and Dose Regimens
NCT01406938 ·Status: COMPLETED ·Phase: PHASE3
-
Etanercept Treatment in Patients With Moderate to Severe Plaque Psoriasis Who Lost Response to Adalimumab
NCT01543204 ·Status: TERMINATED ·Phase: PHASE4
-
Efficacy and Safety Study of Subcutaneous Secukinumab in Treatment of Subjects With Moderate to Severe Chronic Plaque-type Psoriasis as Compared to Etanercept and Placebo.
NCT01900782 ·Status: WITHDRAWN ·Phase: PHASE3
-
A Phase 3 Study of Efficacy and Safety of AK101 in Subjects With Psoriasis
NCT05120297 ·Status: COMPLETED ·Phase: PHASE3
-
A Study of AK111 in Subjects With Moderate-to-severe Plaque Psoriasis
NCT05504317 ·Status: COMPLETED ·Phase: PHASE1
-
Clinical Study of AK101 in Subjects With Moderate to Severe Plaque Psoriasis
NCT04173637 ·Status: COMPLETED ·Phase: PHASE2
-
Study of Safety, Tolerability, and Efficacy of Secukinumab in Subjects With Moderate to Severe Nail Psoriasis
NCT01807520 ·Status: COMPLETED ·Phase: PHASE3
-
Efficacy and Safety of 2 Secukinumab Regimens in 90kg or More Weight Group With Moderate/Severe Chronic Plaque Psoriasis
NCT03504852 ·Status: COMPLETED ·Phase: PHASE3
-
A Dose Ranging Study of AIN457 in Patients With Moderate to Severe Chronic Plaque-type Psoriasis
NCT01071252 ·Status: COMPLETED ·Phase: PHASE2
-
Extension Study up to 3 Years for Secukinumab in Psoriatic Arthritis
NCT01892436 ·Status: COMPLETED ·Phase: PHASE3